Arch Pathol Lab Med. 2025 Jun 1;149(6):e115-e150. doi: 10.5858/arpa.2024-0388-CP.
PMID:40126379
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
FUTURE II Study Group.
N Engl J Med. 2007 May 10;356(19):1915-27. doi: 10.1056/NEJMoa061741.
PMID:17494925
Human Papillomavirus Vaccination and Actinic Keratosis Burden: The VAXAK Randomized Clinical Trial.
Wenande E, Hastrup A, Wiegell S, Philipsen PA, Thomsen NB, Demehri S, Kjaer SK, Haedersdal M.
JAMA Dermatol. 2025 Jun 1;161(6):605-614. doi: 10.1001/jamadermatol.2025.0531.
PMID:40047786
Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific Populations.
Zigras T, Mayrand MH, Bouchard C, Salvador S, Eiriksson L, Almadin C, Kean S, Dean E, Malhotra U, Todd N, Fontaine D, Bentley J.
Curr Oncol. 2023 Jun 9;30(6):5652-5679. doi: 10.3390/curroncol30060425.
PMID:37366908
Human papillomavirus vaccination and Pap test uptake, awareness, and barriers among young adults in Gulf Cooperation Council countries: A comparative cross-sectional survey.
Mahmoud I, Al Eid MMA, Mohamed MA, Aladwani AJ, El Amin NEM.
J Infect Public Health. 2024 Oct;17(10):102525. doi: 10.1016/j.jiph.2024.102525. Epub 2024 Aug 28.
PMID:39243689
A multiplex RPA-CRISPR/Cas12a-based POCT technique and its application in human papillomavirus (HPV) typing assay.
Liu Y, Chao Z, Ding W, Fang T, Gu X, Xue M, Wang W, Han R, Sun W.
Cell Mol Biol Lett. 2024 Mar 8;29(1):34. doi: 10.1186/s11658-024-00548-y.